CurrentViva HealthPolicy IC-0002

Tocilizumab (intravenous) coverage

Policy governing prior authorization, coverage criteria, dosing limits, and renewal requirements for intravenous tocilizumab (Actemra and biosimilars) for Viva Health members in North Carolina.

Policy Summary

PayerViva Health

PolicyTocilizumab (intravenous) coverage

Policy CodePolicy IC-0002

Change TypeNo material change

Effective Date

Next Review DateJul 1, 2025

Key ActionObtain prior authorization (initial approvals typically for 6 months) and document indication-specific clinical baseline and prior therapy trials per policy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsinitial PA duration

600 BUGCA per-dose BU

800 BUMost indications per-dose BU

3200 BUCRS course max

NCapplicable state

HCPCS & NDCbilling codes provided

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Indication-Specific Requirements

Universal Criteria

Covered when ALL of the following universal criteria are met

Universal Criteria: Patient has been evaluated and screened for latent tuberculosis (TB) prior to initiating treatment and will receive ongoing TB monitoring; patient does not have an active infection (including clinically important localized infections); patient will not receive live vaccines during therapy; patient is not on concurrent treatment with another biologic therapy or targeted synthetic therapy.

Supports all indication-specific approvals

General Initial Approval Criteria

Covered when ALL of the following are met

Product-specific and age requirement: Patient must have a contraindication, intolerance, or failure to Tyenne prior to consideration of another intravenous tocilizumab product; AND patient is at least 18 years of age (unless otherwise specified by the indication).

Applies broadly unless indication states different age

Rheumatoid Arthritis (RA)

Covered when ALL of the following are met

RA initial therapy criteria: Physician has assessed baseline disease severity using an objective measure/tool; documented moderate to severe active disease; AND either at least a 3-month trial and failure of ONE conventional synthetic DMARD (e.g., methotrexate, azathioprine, auranofin, hydroxychloroquine, penicillamine, sulfasalazine, leflunomide) OR patient is already established on biologic or targeted synthetic therapy; AND may be used as a single agent or in combination with csDMARDs (e.g., methotrexate, hydroxychloroquine, leflunomide, sulfasalazine).3 months trial

Example csDMARDs listed in policy

Giant Cell Arteritis (GCA)

Covered when ALL of the following are met

GCA initial therapy criteria: Patient has large-vessel arteritis verified by biopsy or imaging (CDUS, MRI, PET-CT, or CT angiography); patient has active disease with an elevated CRP and/or ESR; patient has had an inadequate response to, or has a contraindication or intolerance to, glucocorticoid therapy alone; AND tocilizumab is used in combination with a tapering course of glucocorticoids (note: tocilizumab can be used alone following discontinuation of glucocorticoids).elevated CRP and/or ESR

Imaging modalities listed: CDUS, MRI, PET-CT, CT angiography

Juvenile Idiopathic Arthritis (sJIA/pJIA)

Covered when ALL of the following are met

sJIA/pJIA criteria: Patient is at least 2 years of age; physician has assessed baseline disease severity using an objective tool; patient has active systemic juvenile idiopathic arthritis (sJIA) OR polyarticular juvenile idiopathic arthritis (pJIA); AND either at least a 1-month trial and failure (unless contraindicated/intolerant) of previous therapy with oral NSAIDs OR conventional synthetic DMARDs (e.g., methotrexate, leflunomide, sulfasalazine), OR patient is already established on biologic or targeted synthetic therapy; AND may be used as a single agent or in combination with methotrexate.1 month trial

Examples of csDMARDs listed

Castleman Disease

Covered when ALL of the following are met (one of the branches below)

Castleman disease branches: Used as a single agent AND one of the following branches: (1) Unresectable unicentric disease AND patient is HIV-1 negative AND HHV-8 negative AND used as subsequent therapy for relapsed/refractory/progressive disease; OR (2) Multicentric disease AND used as subsequent therapy for disease that has progressed following treatment of relapsed/refractory/progressive disease; OR (3) Used as a substitute for siltuximab if siltuximab is unavailable or in shortage.

Policy defines HIV and HHV-8 negativity for unresectable unicentric branch

Cytokine Release Syndrome (CRS)

Covered when ALL of the following are met

CRS criteria: Patient is at least 2 years of age; AND either patient has received or will be receiving CAR-T cell therapy and tocilizumab is available/ordered to have on-hand prior to CAR-T administration, OR tocilizumab is used for management of specified CRS scenarios (prolonged >3 days G1 CRS in high-risk patients; G1 CRS persisting >24 hours after axicabtagene ciloleucel or brexucabtagene autoleucel; G1 CRS within 72 hours after lisocabtagene maraleucel; G2-4 CRS; G1-4 neurotoxicity as additional therapy if concurrent CRS), OR used as supportive care for severe CRS related to blinatumomab in ALL, OR used prophylactically to reduce CRS risk with teclistamab-cqyv.age >=2

Specific grade/duration criteria and CAR-T product distinctions listed

Management of Immune Checkpoint Inhibitor-Related Toxicities

Covered when ALL of the following are met

ICI-related toxicities: Patient has been receiving immune checkpoint inhibitor therapy; AND tocilizumab is used as additional therapy for specified immunotherapy-related toxicities such as giant cell arteritis; moderate or severe inflammatory arthritis when patient is unable to taper corticosteroids after one week; polymyalgia rheumatica unable to taper prednisone or with no improvement; moderate (G2) pneumonitis with no improvement after 48-72 hours of corticosteroids; severe (G3-4) pneumonitis with no improvement after 48 hours of methylprednisolone; OR as additional corticosteroid-sparing immunosuppression for specified liver enzyme elevations or HLH-like syndrome not responding to corticosteroids after 5 days.specified timeframes per toxicity

Detailed lab/time criteria for AST/ALT and alkaline phosphatase included

Acute Graft Versus Host Disease (aGVHD)

Covered when ALL of the following are met

aGVHD criteria: Patient has received an allogeneic hematopoietic stem cell transplant; tocilizumab is used for steroid-refractory acute GVHD in combination with systemic corticosteroids as additional therapy after no response to first-line therapies.

Policy references clinician and patient-reported assessment tools for response

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Covered when ALL of the following diagnostic criteria are met

NMOSD seropositive branch: Patient is seropositive for aquaporin-4 (AQP4) IgG antibodies AND patient has at least one core clinical characteristic (e.g., acute optic neuritis, acute myelitis, area postrema syndrome, etc.) AND alternative diagnoses (e.g., MOGAD, MS, sarcoidosis, cancer, chronic infection) have been excluded.AQP4-IgG positive

Core clinical characteristics and some require MRI findings

NMOSD seronegative/unknown branch: Patient is seronegative for AQP4-IgG or AQP4-IgG status is unknown AND patient has at least two core clinical characteristics occurring as a result of one or more clinical attacks; AND at least one core clinical characteristic must be acute optic neuritis, acute myelitis, or area postrema syndrome; AND fulfillment of typical MRI finding requirements for each affected area; AND alternative diagnoses have been excluded.>=2 core clinical characteristics

MRI fulfillment requirements specified per affected area

Indication response criteria

Covered when evidence of disease response or stabilization is documented per indication-specific measures

Rheumatoid arthritis: Demonstrated improvement in signs and symptoms compared to baseline such as tender and swollen joint counts, reduction in C-reactive protein, improvement in patient global assessment, and/or improvement on a disease activity scoring tool (e.g., DAS28 improvement ≥1.2 points or ACR20 ≥20%).DAS28 ≥1.2 change or ACR20 ≥20%

Used to justify continuation or response

Giant cell arteritis: Demonstrated improvement in signs and symptoms compared to baseline such as headache, temporal artery tenderness, visual symptoms, inflammatory parameters (ESR, CRP), or improvement on periodic imaging studies (CDUS, MRI, PET-CT, CTA).clinical and lab/imaging improvement

Used to justify continuation or response

Juvenile idiopathic arthritis (polyarticular/systemic):

Dosing by indication

Covered dosing regimens by indication and weight

Adult rheumatoid arthritis dosing: Administer 4 mg/kg IV every 4 weeks; may increase to 8 mg/kg every 4 weeks based on clinical response, up to a maximum of 800 mg per dose.max 800 mg/dose

See dosage/administration section

Polyarticular juvenile idiopathic arthritis dosing: Weight ≥30 kg: 8 mg/kg IV every 4 weeks; Weight <30 kg: 10 mg/kg IV every 4 weeks.weight-based dosing

Pediatric weight tiers specified

Systemic juvenile idiopathic arthritis dosing: Weight ≥30 kg: 8 mg/kg IV every 2 weeks; Weight <30 kg: 12 mg/kg IV every 2 weeks.weight-based dosing

Covered Diagnoses

Covered diagnosis codes (Appendix 1)

Covered ICD-10 codes: Services for which an applicable ICD-10 diagnosis from Appendix 1 is submitted may be considered for coverage per the policy's medical necessity criteria.

Appendix lists codes by condition and anatomical site

Coverage is not appropriate for members who do not meet the policy's universal safety conditions. Specifically, approval is contingent on the member being screened for latent tuberculosis and undergoing ongoing TB monitoring; the absence of any active infection; avoidance of live vaccines during therapy; and not receiving concurrent another biologic or targeted synthetic therapy. Requests that conflict with these contraindications may be denied.

Per the coding guidance, use of the miscellaneous HCPCS code J3590 for tocilizumab products is limited. The policy notes that J3590 should be discontinued for Avtozma and the unbranded tocilizumab-anoh IV product effective 10/01/2025; providers should bill using the specific HCPCS/Q-codes listed for each product when available.

For Medicare members, providers must follow applicable CMS rules. National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and MAC jurisdiction rules may impose additional or different coverage requirements; where Medicare guidance applies it takes precedence. Providers should consult the CMS coverage database for relevant NCDs/LCDs/LCAs when submitting claims.

As a general step-therapy requirement, the policy requires that the patient have a documented contraindication, intolerance, or failure to Tyenne® before another intravenous tocilizumab product is considered, unless an indication-specific exception applies. This requirement also notes age criteria (typically ≥18 years) unless the indication states otherwise.

Dosing must conform to the indication-specific maximums. In particular, the policy specifies that doses should not exceed 800 mg per infusion for most indications (and CRS patients) and should not exceed 600 mg per infusion for Giant Cell Arteritis. Requests for doses above these per-infusion limits require documentation of rationale and may be considered not medically necessary without justification.

Billing, Units, HCPCS, NDCs, and ICD-10 Appendix

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is required for IV tocilizumab products billed under the listed HCPCS/NDC codes and is typically issued initially for 6 months unless an indication-specific exception applies (e.g., CRS initial approval up to 4 doses; Management of Immune Checkpoint Inhibitor‑Related Toxicities initial approval for 1 dose only). Prior authorization requirements not specified elsewhere in this section should be confirmed by referring to other policy sections or the payer's PA portal.

Initial PA validity generally = 6 months (see indication exceptions)
CRS: initial PA up to 4 doses; CRS PAs may NOT be renewed
Management of Immune Checkpoint Inhibitor‑Related Toxicities: initial PA for 1 dose; may NOT be renewed

Denial Risk

Diagnosis Code Required and Must Match Covered List

The prior authorization request and claims must include an applicable covered ICD‑10 diagnosis code from Appendix 1 that corresponds to the requested indication. Claims or PA requests that do not use one of the listed covered ICD‑10 diagnosis codes are at risk for denial.

Background and Drug Overview

Tocilizumab is an interleukin-6 receptor antagonist indicated for multiple inflammatory and immune-mediated conditions. The policy supports its use for FDA‑approved and compendia-recognized indications including rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, Castleman disease, cytokine release syndrome, certain immune checkpoint inhibitor–related toxicities, acute graft-versus-host disease, and neuromyelitis optica spectrum disorder.

Clinical Response Definitions and Grading

Core clinical characteristics and typical MRI findings for NMOSD

Core clinical characteristicsAcute optic neuritis; acute myelitis; acute area postrema syndrome (persistent unexplained hiccups/nausea/vomiting ≥48 hours or dorsal brainstem MRI lesion); acute brainstem syndrome; symptomatic narcolepsy or diencephalic syndrome; acute cerebral syndrome with NMOSD-typical MRI lesions

Typical MRI findings — optic neuritisNormal cerebral MRI or longitudinally extensive optic nerve lesion (≥ half optic nerve length or involving optic chiasm) on T2 or T1/Gd

Typical MRI findings — myelitisIntramedullary lesion ≥3 contiguous vertebral segments (LETM) or focal atrophy ≥3 contiguous VS

Typical MRI findings — area postremaLesion in the dorsal medulla/area postrema

Rheumatoid arthritis response — typical response measures

Policy Revision History

2025-07-01policy_review

Document last reviewed on 2025-07-01 per policy metadata; regular review cadence indicated with next review on 2025-07-01.

prior_auth_validity_summary

Initial prior authorizations are typically valid for 6 months; indication-specific exceptions: CRS initial validity limited to up to 4 doses, and immune checkpoint inhibitor–related toxicities initial validity limited to a single dose (renewal rules vary by indication).

renewal_cadence_summary

Renewals: prior authorization may be renewed annually unless specified; aGVHD and Castleman Disease renewals may be every 6 months; CRS and immune checkpoint inhibitor–related toxicities are not eligible for renewal; GCA may be renewed up to a maximum of 18 months of therapy.

Policy Summary

PayerViva Health

PolicyTocilizumab (intravenous) coverage

Policy CodePolicy IC-0002

Change TypeNo material change

Effective Date

Next Review DateJul 1, 2025

Key ActionObtain prior authorization (initial approvals typically for 6 months) and document indication-specific clinical baseline and prior therapy trials per policy.

SourceLink

On This Page

Demonstrated improvement in joint counts, reduction in CRP, improvement in patient global assessment, or improvement on disease activity scoring tools (e.g., JADAS or ACR‑Pedi 30 with at least 30% improvement in 3 of 6 variables).

ACR‑Pedi 30 ≥30% in 3 of 6 variables

Used to justify continuation or response

NMOSD: Stabilization or improvement including decreased acute relapses, reduced hospitalizations, reduction/discontinuation in plasma exchange treatments, or reduction/discontinuation of corticosteroids without relapse.clinical stabilization or fewer relapses

Used to justify continuation or response

Pediatric weight tiers specified

Castleman disease dosing: Administer 8 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.ongoing until progression/toxicity

Per dosage/administration

Cytokine release syndrome dosing: Weight ≥30 kg: 8 mg/kg IV every 8 hours if needed, up to a maximum of 4 total doses; Weight <30 kg: 12 mg/kg IV every 8 hours if needed, up to a maximum of 4 total doses. If no improvement after the first dose, up to 3 additional doses may be given with at least 8-hour intervals. Doses exceeding 800 mg per infusion are not recommended in CRS patients.max 4 doses; do not exceed 800 mg per infusion

CRS course and dosing limits specified

Management of immune checkpoint inhibitor-related toxicities dosing: Administer up to 8 mg/kg IV one time only; additional doses may be approved on a case-by-case basis.single dose standard

Additional doses case-by-case

Acute GVHD dosing: Administer 8 mg/kg IV every 2-4 weeks until disease progression or unacceptable toxicity.ongoing until progression/toxicity

Per dosage/administration

NMOSD dosing: Administer 8 mg/kg IV every 4 weeks.8 mg/kg every 4 weeks

Per dosage/administration

Giant cell arteritis dosing: Administer 6 mg/kg IV every 4 weeks in combination with a tapering course of glucocorticoids; doses exceeding 600 mg per infusion are not recommended. Tocilizumab can be used alone following discontinuation of glucocorticoids.max 600 mg per infusion for GCA

Per dosage/administration

Use Appendix 1 — listed ICD‑10 codes only
Diagnosis code on PA must match one of the covered diagnoses for the indication
Diagnosis-code mismatch is a common cause for denial

Documentation Required

Required Clinical Documentation

Document objective baseline disease severity and relevant clinical measures prior to initiation (e.g., tender/swollen joint counts, CRP/ESR, DAS28/ACR20/RAPID3 for RA; JADAS or ACR‑Pedi scores for JIA). Also provide evidence of prior therapy trials, contraindications, or intolerance where required by indication-specific criteria.

Baseline disease severity assessment (objective tool) for RA and JIA
For RA: record tender/swollen joint counts, CRP reduction, patient global assessment, and/or DAS28/ACR20/RAPID3 results
For JIA: document JADAS or ACR‑Pedi response measures (e.g., ≥30% improvement in required variables)
Record prior csDMARD trials (duration and outcome) or existing use of biologic/targeted synthetic therapy

Documentation Required

Clinical Contraindications and Safety Checks

Clinical contraindications and safety checks must be documented before and during therapy. These include screening for latent tuberculosis, absence of active infection, avoidance of live vaccines during treatment, and not administering concurrent biologic or targeted synthetic therapy unless explicitly allowed.

TB screening documented prior to initiation and ongoing monitoring during treatment
No active or clinically important localized infections
No live vaccines during therapy
Not on concurrent biologic or targeted synthetic therapy

Step Therapy

Step Therapy / Prior Treatment Requirements

Step therapy requirements must be met when applicable. For certain indications, patients must have a documented contraindication, intolerance, or failure to Tyenne® (tocilizumab-aazg) prior to consideration of another intravenous tocilizumab product, unless the patient is already established on a biologic or targeted synthetic therapy.

Document 3‑month trial and failure of listed csDMARDs for RA where required
If step therapy specifies Tyenne®, document trial and failure or contraindication/intolerance to Tyenne®

Documentation Required

Clinical and Dosing Documentation / Response‑Based Justification

Clinical and dosing information must be provided to support the requested regimen: patient weight, indication‑specific dosing, frequency, and clinical response measures. For continuation approvals, provide documentation of response compared to baseline per indication (response‑based justification).

Include patient weight and requested dose (mg and mg/kg) and frequency
Reference indication-specific dosing limits (e.g., adult RA 4 mg/kg q4w may increase to 8 mg/kg up to 800 mg)
For CRS include number of doses requested (max 4 doses) and clinical response to prior doses if applicable
Provide objective measures showing clinical response for continuation (e.g., improvement in DAS28, ACR criteria, JADAS/ACR‑Pedi)

Billing Rule

Coding and Diagnosis Alignment (Billing Rule)

Coding and diagnosis alignment is required: ensure the HCPCS/NDC code used for billing matches the specific tocilizumab product and that the billed diagnosis is one of the covered ICD‑10 codes in Appendix 1. Lack of appropriate HCPCS/NDC coding or absence of a covered diagnosis code may trigger denial.

Use the HCPCS codes listed for IV tocilizumab (e.g., J3262, Q5133, Q5135, Q5156) or the appropriate NDC/HCPCS for the product administered
Do not bill an unlisted code without prior authorization justification — J3590 usage may be scrutinized
Ensure the billed ICD‑10 code aligns to the covered diagnosis list in Appendix 1

Improvement in tender and swollen joint counts, reduction in C-reactive protein, improvement in patient global assessment

Validated tool thresholdsDAS28 improvement ≥1.2 points or ACR20 ≥20% can indicate response

Other assessmentsRAPID3 or other composite disease activity indices may be used

Giant cell arteritis response — typical response measures

Clinical response indicatorsImprovement in headache, temporal artery tenderness, visual symptoms

Laboratory/imaging responseReduction in ESR/CRP and improvement on periodic imaging (CDUS, MRI, PET-CT, CTA)

ContextUsed to document therapeutic response and guide continuation/tapering of glucocorticoids

Juvenile idiopathic arthritis response — typical response measures

Response measuresImprovement in tender and swollen joint counts, reduction in CRP, improvement in patient global assessment

Validated tool thresholdsJADAS or ACR-Pedi 30 with ≥30% improvement in 3 of 6 variables indicates response

Age considerationsApplies to systemic or polyarticular juvenile idiopathic arthritis per weight-based dosing and assessment

NMOSD response — stabilization or improvement metrics

Response/stabilization criteriaDecreased acute relapses or improved stability of neurologic symptoms

Other indicatorsReduced hospitalizations; reduction/discontinuation of plasma exchange or corticosteroids without relapse

PurposeUsed to justify ongoing therapy for NMOSD

Cytokine release syndrome (CRS) — ICD-10 codes and grading

ICD-10 codes for CRS gradesD89.831 (grade 1), D89.832 (grade 2), D89.833 (grade 3), D89.834 (grade 4)

Unspecified grade codeD89.839 = Cytokine release syndrome, grade unspecified

UsageUse these codes to indicate CRS grade on claims and documentation

Immune effector cell-associated neurotoxicity syndrome (ICANS) — ICD-10 codes and grading

ICD-10 codes for ICANS gradesG92.01 (grade 1), G92.02 (grade 2), G92.03 (grade 3), G92.04 (grade 4)

Unspecified codeG92.00 = Immune effector cell-associated neurotoxicity syndrome, grade unspecified

UsageUse these codes to indicate ICANS grade on claims and documentation

Rheumatoid arthritis (ICD M06.* / M08.* / M09.* series) — enumerated codes

ICD-10 series coveredM06.* / M08.* / M09.* series (multiple specific RA and juvenile RA codes enumerated)

ExamplesM06.021, M06.022, M06.031, etc. listed in Appendix 1

Documentation tipUse specific anatomical-site codes from Appendix 1 on claims to reflect covered RA diagnoses

Giant cell arteritis / polymyalgia rheumatica — included ICD-10 codes M31.5, M31.6, and M35.3

Included ICD-10 codesM31.5 (Giant cell arteritis with polymyalgia rheumatica), M31.6 (Other giant cell arteritis), M35.3 (Polymyalgia rheumatica)

UsageSubmit one of these covered diagnosis codes from Appendix 1 when requesting coverage for GCA/PMR-related treatment

ContextCodes are listed under Appendix 1 - Covered Diagnosis Codes

step_therapy_note

Policy requires prior trial of Tyenne® (unless contraindicated/intolerant/failed) before other IV tocilizumab products for most indications, which affects PA approvals and validity.

2025-07-01timeline_entryLatest

Policy status current with last review dated 2025-07-01; prior authorization validity and indication-specific renewal cadence described in policy (initial 6 months standard).